
Mitscor 90mg Tablet
Marketer
Mits Healthcare Pvt Ltd
Salt Composition
Ticagrelor (90mg)
Overview Mitscor 90mg Tablet
Ticagrelor 90mg tablets are classified as antiplatelet agents, effectively reducing the likelihood of harmful blood clot formation within blood vessels. This action helps mitigate the risk of heart attack or stroke in patients with pre-existing cardiac conditions. These tablets are also indicated for individuals recovering from a recent heart attack or experiencing severe angina pectoris (unstable angina), particularly those who have undergone coronary stenting. Their preventative role extends to minimizing the recurrence of heart attacks, strokes, and stent thrombosis. Concurrent use with aspirin, another antiplatelet drug, is typically prescribed by your physician. Ticagrelor 90mg tablets can be administered with or without food, consistently at the same time daily. Continued use is vital, even in the absence of symptoms, as discontinuation raises the risk of cardiovascular events. The most prevalent adverse effect is bleeding; minor cuts or injuries may exhibit prolonged bleeding times, although generally resolving spontaneously. Some patients experience mild dyspnea, which usually subsides with continued therapy. Persistent bleeding or worsening/unresolved shortness of breath warrants immediate medical attention. This medication is contraindicated in individuals with active internal bleeding (e.g., from ulcers or intracranial hemorrhage) or hepatic impairment. Always disclose any such conditions to your doctor prior to commencing treatment.
Uses of Mitscor 90mg Tablet
Reducing the risk of cardiovascular events
Major Benefits of Mitscor 90mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Mitscor 90mg Tablets can be administered with or without food, though consistent timing is recommended.
Common Side effects of Mitscor 90mg Tablet:
- Bleeding
- Breathlessness
How to use Mitscor 90mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 90mg Mitscor Tablet whole; do not crush, chew, or divide it. This medication can be taken with or without food, however, consistency in timing is recommended.
How Mitscor 90mg Tablet works:
Aggrenox 90mg tablets inhibit platelet aggregation, reducing the risk of potentially dangerous thrombus formation and consequently lowering the likelihood of cardiovascular events such as myocardial infarction or cerebrovascular accident.
SAFETY ADVICE
AlcoholCAUTION
Use caution when drinking alcohol while taking Mitscor 90mg Tablets. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
Use of Mitscor 90mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Data on the compatibility of Mitscor 90mg Tablet with breastfeeding is currently unavailable. Seek medical advice from your physician.
DrivingSAFE
Driving ability is typically unaffected by Mitscor 90mg Tablets.
KidneySAFE IF PRESCRIBED
Mitscor 90mg tablets are considered safe for individuals with kidney disease, and no dosage modification is advised. Data regarding Mitscor 90mg tablet use in patients undergoing renal dialysis is currently limited.
LiverCAUTION
Patients with liver impairment should use Mitscor 90mg Tablets cautiously, potentially requiring dosage modification. A physician's consultation is advised. Mitscor 90mg Tablets are contraindicated in individuals with advanced hepatic dysfunction.
What if you forget to take Mitscor 90mg Tablet :
Should you forget a Mitscor 90mg Tablet dose, administer it promptly. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Mitscor 90mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Triazolopyrimidine derivatives |
| Developing Habits | No. |
| Type of Treatment | KINSHIP |
| Action Class | ADP receptor antagonists (P2Y12 inhibitors) |
